Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Corbus Pharmaceuticals Holdings Q3 2026 Results: Net Loss of $37.8M, Loss Widens

Corbus Pharmaceuticals reported a net loss of $95.8 million for the nine months ended September 30, 2026, driven by a significant increase in research and development expenses related to its ADC and obesity pipelines. The company's cash and investment position decreased to approximately $115.3 million from $163.3 million at the end of 2025, despite raising $27.6 million through common stock issuances.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-37.8-23.3
EPS (diluted, $ a share)$-1.81$-1.90

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: CRBP. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Corbus Pharmaceuticals Holdings, Inc.: key numbers

Share price
$3.38Close, Nov 16
Market cap
$69.5M
Shares outstanding
20.61MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Corbus Pharmaceuticals Holdings, Inc.

All →
8:10 AM ET 8-K
Clinical Trial Data

Corbus Pharmaceuticals Holdings Clinical Trial Data

Corbus Pharmaceuticals announced positive Phase 1b clinical trial data for CRB-913, an oral non-incretin therapy for obesity, presented at ObesityWeek 2026. The CANYON-1 trial demonstrated statistically significant weight loss across all doses, with the 60 mg cohort achieving a 5% mean weight loss at 12 weeks and a favorable safety profile with low discontinuation rates.

Term
16 weeks

“In the CANYON-1 trial, CRB-913 was safe and well tolerated while demonstrating clinically meaningful weight loss as an oral therapy via a distinct, non-incretin mechanism. We’re encouraged that CRB-913 has emerging potential as a novel therapeutic option for people living with obesity and look forward to future development.”

Yuval Cohen, Ph.D., Chief Executive Officer of Corbus
8:08 AM ET 8-K
Financial Results

Corbus Pharmaceuticals Holdings Financial Results

Corbus Pharmaceuticals reported Q3 2026 financial results and provided updates on its clinical pipeline, including the initiation of the TEMPO-1 registrational study for sutantatug envedotin in oropharyngeal cancer. The company also reported positive topline data from its CANYON-1 Phase 1b obesity study, showing 5% mean weight loss at 12 weeks for its CB1 inverse agonist CRB-913. Corbus ended the quarter with $145.6 million in cash and cash equivalents, providing a projected runway into Q3 2027.

“The commencement of the TEMPO-1 trial marks our transition to late-stage clinical development, bringing us meaningfully closer to delivering sutantatug envedotin as a potentially novel, targeted therapeutic for those impacted by OPSCC who were previously treated with platinum-based and anti-PD1 therapy.”

Yuval Cohen, Ph.D., Chief Executive Officer of Corbus

“For CRB-913, our topline CANYON-1 data demonstrated, for the first time, that a highly peripherally restricted CB1 inverse agonist can deliver a safe and tolerable therapeutic alternative with competitive weight loss to oral GLP-1s.”

Yuval Cohen, Ph.D., Chief Executive Officer of Corbus
4:06 PM ET Form 4
Insider Selling

Corbus Pharmaceuticals Holdings Insider Cormorant Asset Management LP Sells $1.74M of Stock

Cormorant Asset Management LP sold 425,000 shares of Corbus Pharmaceuticals Holdings, Inc. at $4.10 a share, worth $1.74M in total on Oct 29, 2026. Shares held after the trade: 1,919,971 (-18.1%).

Value
$1.74M
Shares
425,000
Price
$4.10
Holding change
-18.1%
Trade date
Oct 29, 2026
10:28 AM ET 8-K
Investor Presentation

Corbus Pharmaceuticals Holdings Investor Presentation

Corbus Pharmaceuticals updated its corporate investor presentation to highlight its clinical pipeline in oncology and obesity. Key focus areas include the CRB-701 Nectin-4 ADC, which is entering a registrational Phase 2 study for OPSCC, and CRB-913, a CB1 inverse agonist for obesity with a Phase 2 study expected to start in the first half of 2027.

7:07 AM ET 8-K
Clinical Trial Data

Corbus Pharmaceuticals Holdings Clinical Trial Data

Corbus Pharmaceuticals announced positive topline results from its CANYON-1 Phase 1b clinical trial of CRB-913 for the treatment of obesity. The study met its primary objectives, demonstrating statistically significant weight loss of 5% at the 60 mg dose over 12 weeks with a favorable safety profile and no evidence of weight loss plateauing. The data supports CRB-913's potential as a first-in-class oral, non-incretin obesity medicine.

Term
16 weeks
Earnings call
Sep 14, 2026, 8:00 AM ET

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.